Table 1

Demographic and clinicopathological characteristics of included studies

First author	Year	Country	Institution	Years recruiting	N	Median age, years* (range)	PMP	Stage				LND	RT	CT	HT	Median follow-up, months* (range)
First author	Year	Country	Institution	Years recruiting	N	Median age, years* (range)	PMP	I	II	III	IV	LND	RT	CT	HT	Median follow-up, months* (range)
Agarwal et al6	2017	India	Amrita Institute of Medical Sciences	2005–2016	28	N/A	N/A	N/A				N/A	N/A	N/A	N/A	N/A
Amant et al 7	2007	Belgium	Katholieke University Leuven	1986–2005	31	44 (18–60)	81%	22	0	4	5	6	0	0	7	N/A
Beck et al8	2012	USA	Cleveland Clinic, Roswell Park, Magee	1986–2002	42	44.8 (27–73)	N/A	28	1	8	3	9	5	4	14	130
Berchuck et al9	1990	USA	Memorial Sloan Kettering	1970–1984	22	48	N/A	19	1	2	0	0	3	3	0	N/A
Cheng et al10	2011	USA	MD Anderson	1995–2006	74	43.5 (22–68)	82%	N/A				18	9	3	27	76 (2–444)
Chu et al 11	2003	USA	Yale Universtity	1978–2003	22	45.5 (19–76)	72.7%	17	0	4	1	7	1	0	13	100 (2–258)
Evans et al12	1982	USA	MD Anderson	N/A	11	39 (20–60)	91%	7	2	0	2	0	8	2	1	N/A
Feng et al14	2011	China	Fudan University	1992–2007	57	43 (19-63)	N/A	45	12	0	0	36	6	47	0	68 (17–140)
Gaducci et al15	1996	Italy	Mutlicenter (Italy)	1980–1994	26	44 (18–68)	N/A	19	1	4	2	7	4	5	1	92 (4–167)
Huang et al16	1996	Taiwan	National Taiwan University	1965–1994	17	43.5 (24–75)	85%	7	0	8	2	1	4	1	10	48.1 (15–173)
Li et al5	2005	USA	Johns Hopkins, UCLA, UTSW, Jefferson	n/a	36	46 (26–50) for OP, 45 (25–59) for bilateral salpingo-oophorectomy	80.5%	36	0	0	0	N/A	4	0	8	34.8 for ovarian preservation and 60 for bilateral salpingo-oophorectomy
Malouf et al13	2009	France	Institut Gustav	1977–2007	54	47 (25–73)	76%	48	6	0	0	4	14	3	10	58 (3–348)
Mansi et al19	1990	UK	Royal Marsden Hospital	1973–1987	8	37 (30–50)	75%	6	0	1	1	0	3	0	0	45 (8–128)
Norris et al20	1966	USA	Armed Forces Database	N/A	18	N/A	N/A	N/A				N/A	N/A	N/A	N/A	N/A
Stewart et al18	2018	USA	University of Washington	1985–2014	112	48.5 (22–87)	N/A	49	8	20		36	4*	1*	28*	55 (1–325)
Yoon et al3	2013	South Korea	Samsung Medical Center, Asan Medical Center	1990–2012	114	45 (18–74)	77.2%	92	9	4	9	45	12	20	12	46 (0.5–251)
Zhou et al17	2015	China	Xiamen Cancer Center	1991–2013	114	41 (19–58)	86%	77	12	22	3	71	36	56	11	40 (3–172)
Total				1965–2013	786			472	53	105		240	113	145	142

BOLD: mean,
*Information on adjuvant treatment available for 51 patients.
CT, Chemotherapy; HT, hormonal therapy; LND, lymphadenectomy; PMP, premenopausal; RT, radiation therapy.